SG Americas Securities LLC Takes $173,000 Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

SG Americas Securities LLC bought a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the third quarter, according to its most recent disclosure with the SEC. The firm bought 8,710 shares of the biopharmaceutical company’s stock, valued at approximately $173,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. Arizona State Retirement System raised its stake in shares of Catalyst Pharmaceuticals by 2.2% in the second quarter. Arizona State Retirement System now owns 29,733 shares of the biopharmaceutical company’s stock worth $461,000 after buying an additional 654 shares during the period. Ameritas Investment Partners Inc. raised its stake in Catalyst Pharmaceuticals by 6.9% during the 1st quarter. Ameritas Investment Partners Inc. now owns 11,116 shares of the biopharmaceutical company’s stock worth $177,000 after acquiring an additional 720 shares during the period. XTX Topco Ltd lifted its holdings in Catalyst Pharmaceuticals by 7.5% during the second quarter. XTX Topco Ltd now owns 11,134 shares of the biopharmaceutical company’s stock valued at $172,000 after purchasing an additional 773 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Catalyst Pharmaceuticals by 72.9% in the first quarter. GAMMA Investing LLC now owns 1,942 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 819 shares during the period. Finally, Strategic Advocates LLC increased its stake in shares of Catalyst Pharmaceuticals by 6.5% in the second quarter. Strategic Advocates LLC now owns 14,142 shares of the biopharmaceutical company’s stock worth $219,000 after purchasing an additional 864 shares in the last quarter. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Catalyst Pharmaceuticals

In other news, Director David S. Tierney sold 15,000 shares of the firm’s stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $20.10, for a total transaction of $301,500.00. Following the transaction, the director now owns 348,874 shares in the company, valued at approximately $7,012,367.40. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other Catalyst Pharmaceuticals news, insider Steve Miller sold 150,000 shares of Catalyst Pharmaceuticals stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $20.35, for a total value of $3,052,500.00. Following the transaction, the insider now directly owns 675,124 shares of the company’s stock, valued at approximately $13,738,773.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David S. Tierney sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $20.10, for a total value of $301,500.00. Following the completion of the sale, the director now directly owns 348,874 shares of the company’s stock, valued at approximately $7,012,367.40. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 201,058 shares of company stock worth $4,018,188 in the last 90 days. 11.00% of the stock is owned by corporate insiders.

Catalyst Pharmaceuticals Trading Down 0.6 %

NASDAQ:CPRX opened at $21.34 on Thursday. The business’s 50-day moving average is $20.31 and its 200 day moving average is $17.53. Catalyst Pharmaceuticals, Inc. has a 12 month low of $11.89 and a 12 month high of $21.85. The company has a market capitalization of $2.52 billion, a P/E ratio of 39.52, a P/E/G ratio of 3.18 and a beta of 0.76.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.39 by $0.13. Catalyst Pharmaceuticals had a net margin of 15.69% and a return on equity of 27.77%. The company had revenue of $122.71 million during the quarter, compared to analyst estimates of $111.76 million. On average, research analysts forecast that Catalyst Pharmaceuticals, Inc. will post 1.82 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages recently weighed in on CPRX. Citigroup upped their target price on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a report on Friday, August 9th. HC Wainwright upped their price objective on Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Truist Financial lifted their target price on Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Finally, StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Catalyst Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $29.50.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.